Mastering Money 2/24/21
In January of last year, employees of Novavax Inc. met at a local Maryland bar to discuss how they might salvage their careers. For decades, the small biotech had tried to develop a big selling vaccine, with no success. The company had enough cash to survive only another six months or so and its shares traded under $4, with a market value of $127 million dollars. Today, Novavax is advancing toward authorization of a huge Covid-19 vaccine. Scientists believe that, if cleared, it could be one of the best, offering key possible advantages over its competitors. Some early data suggest the Novavax shot may be one of the first shown to stem asymptomatic spread of the coronavirus. It’s vaccine does not require freezing, another big advantage. Suddenly Novavax has a market value of $15.4 billion dollars, greater than that of drug giant Teva Pharmaceuticals! But should you buy the stock, which is up 106% this year? We’ll review an in-depth Wall Street Journal report for you, then Medicare expert Shelley Grandidge joins us. A fact filled show you don’t want to miss…MASTERING MONEY is on the air!!!